Life Science Investing Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update
Life Science Investing Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease
Life Science Investing Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders®
Life Science Investing Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease
Life Science Investing Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation
Life Science Investing Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update
